Name: The Global Pharmaceutical Industry: The Demise and the Path to Recovery (Routledge Advances in Management and Business Studies) (en Inglés)
Price: 126200.00 CLP
Availability: InStock
Author: Daniel Hoffman; Allan Bowditch
ISBN: 9780367485511

portada The Global Pharmaceutical Industry: The Demise and the Path to Recovery (Routledge Advances in Management and Business Studies) (en Inglés)

Formato

Libro Físico

Editorial

Routledge

Autor

Daniel Hoffman; Allan Bowditch

Año

2020

Idioma

Inglés

N° páginas

130

Encuadernación

Tapa Dura

ISBN13

9780367485511

N° edición

Categorías

Estrategia empresarial

The Global Pharmaceutical Industry: The Demise and the Path to Recovery (Routledge Advances in Management and Business Studies) (en Inglés)

Daniel Hoffman; Allan Bowditch (Autor) · Routledge · Tapa Dura

Libro Nuevo

$ 126.200

$ 229.460

Ahorras: $ 103.260

45% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Martes 25 de Junio y el Martes 09 de Julio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "The Global Pharmaceutical Industry: The Demise and the Path to Recovery (Routledge Advances in Management and Business Studies) (en Inglés)"

The pharmaceutical industry, long thought of as a recession-proof investment, now faces a day of reckoning. The reasons for this impending downfall are not hard to discern. The prices the industry charges for its prescription drugs have escalated at four to five times the cost-of-living increases during the past two decades and have reached a point where 30% of Americans must choose between filling a prescription, paying for housing, and buying food. This has brought about public pressure on governments around the world to control drug prices, yet the world's twenty largest pharma companies realized 80% of their growth as a result of exorbitant price hikes. Pharma currently enjoys its extraordinary profitability by exploiting the world's most vulnerable populations. Yet even their ability to increase prices in the face of falling demand does not satisfy their profit demands. The breadth and depth of pharma's marketing transgressions exceed those of any other industry and have now reached a point where authorities around the world have found it necessary to take legal action against its violations. Drastic change is needed if the pharmaceutical industry can equitably advance the health of the world's population and regain public esteem. This book illustrates the range and extent of pharma's violations and addresses the actions that should be implemented in order to make the drug industry a more constructive, less venal part of contemporary society. It will be of interest to researchers, academics, practitioners, and students with an interest in the pharmaceutical industry, healthcare management, regulation, and bioethics.